

Mazlan-Kepli, W., Macisaac, R. L., Walters, M., Bath, P. M.W. and Dawson, J. (2017) Antiplatelet therapy following ischaemic stroke – continue or change pre-existing therapy? *European Stroke Journal*, 2(1), pp. 31-36. (doi:<u>10.1177/2396987316678728</u>)

This is the author's final accepted version.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

http://eprints.gla.ac.uk/153816/

Deposited on: 24 January 2018

 $Enlighten-Research \ publications \ by \ members \ of \ the \ University \ of \ Glasgow \ \underline{http://eprints.gla.ac.uk}$

Antiplatelet therapy following ischaemic stroke – Continue or change pre-existing therapy?

Author(s):

Wardati Mazlan-Kepli¹ Rachael L. MacIsaac¹ Matthew Walters¹ Philip Michael William Bath² Jesse Dawson¹ **On behalf of the VISTA Collaborators.**

¹Institute of Cardiovascular and Medical Sciences, University of Glasgow, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK

²Stroke Trials Unit, University of Nottingham, Nottingham NG7 2UH, UK

Corresponding author:

Jesse Dawson, Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary, Life Sciences, University of Glasgow, Glasgow, UK.

E-mail:jesse.dawson@glasgow.ac.uk

Short title:

Continue or change pre-existing AP?

ABSTRACT

Introduction: Antiplatelet therapy is routinely prescribed early after ischaemic stroke. Many patients will already be taking antiplatelet therapy and it is unknown whether these patients should continue the same antiplatelet treatment or switch to a different regimen.

Methods: We selected patients with ischaemic stroke **from the Virtual International Stroke Trials Archive (VISTA) database** who were prescribed anti-platelets both before and after their stroke and who had detailed records of adverse events after stroke. We compared patients who changed to a new antiplatelet regimen after their stroke to those who continued the same regimen. The primary outcome was recurrent ischaemic stroke within 90 days after their index stroke and for secondary outcome was intracerebral haemorrhage (ICH) or extracranial haemorrhage (ECH). We used **logistic regression** analysis and adjusted for age and baseline NIHSS.

Results: A total of 1129 participants were included. Of these, 538 subjects changed antiplatelet regimen post stroke and 591 continued the same regimen. A recurrent ischaemic event occurred in 4.1% of subjects who changed regimen and 4.3% who continued unchanged (adjusted OR=0.93; 95% CI 0.54-1.75, p=0.929). The incidence of ICH and ECH within the first 90 days was similar in both groups (2.4% vs. 2.6% (adjusted OR=1.02; 95% CI 0.48-2.18, p=0.955) and 4.7% vs. 2.9% (adjusted OR=1.82; 95% CI 0.96-3.43, p=0.065) respectively).

Conclusion: In patients who suffer ischaemic stroke whilst taking antiplatelets, a change in antiplatelet regimen was not associated with an altered risk of early recurrent ischaemic stroke rate or bleeding. However, the results must be interpreted in view of the low event rates.

Keywords

antiplatelet, recurrent ischaemic stroke, intracerebral haemorrhage, outcomes, thrombolysis, prior antiplatelet

Introduction

Antiplatelet therapy is recommended for patients with ischaemic stroke or transient ischaemic attack (TIA) due to atherosclerotic disease.¹ Antiplatelet drugs are prescribed to prevent further ischaemic stroke, minimize the risk of early death and to improve long-term outcome.^{2, 3}

Guidelines recommend that antiplatelet regimens choices are individualised based on numerous factors including patient risk factor profiles, cost, tolerability and relative effectiveness.⁴ One potentially important factor is pre-existing anti-platelet therapy. In the recently published CHANCE study, at least 20% of patients had history of previous stroke and 11% of patients had their index stroke whilst taking antiplatelet therapy.⁵ Guidelines acknowledge that in patients who experience a stroke whilst taking antiplatelet agents decreases the risk of subsequent events.⁶ There are reasons why switching regimen may be advantageous. Failure of antiplatelet treatment could be due to disease severity (no drug will be 100% effective), lack of adherence or resistance to effect of the antiplatelet drug. Resistance to clopidogrel and aspirin exists and studies have shown that aspirin resistance is associated with an increased risk of cardiovascular events.⁷ It is possible resistant patients should be switched to another class of antiplatelet.

In the absence of clinical trial data, we sought to assess whether switching antiplatelet regimens associated with better outcome than continuing the same therapy in patients already taking anti-platelet therapy at the time of acute ischaemic stroke. We hypothesized that a change of antiplatelet regimen would reduce cardiovascular event rate without increasing bleeding.

Methods

We used data contained in the Virtual International Stroke Trials Archive (VISTA) database where have been described previously.⁸ VISTA data are stored at the Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK. It provides access to anonymised data collated from completed and monitored clinical trials. Within VISTA, demographic data such as age, sex and ethnicity; smoking history and comorbidities as well as details on the index stroke, and functional outcome measures are contained. Information on adverse events (AE), serious adverse events (SAE), laboratory measurements and prescribed medications are also available from certain trials. All clinical trials within VISTA already have local institutional review board approved procedures in accordance with the Declaration of Helsinki. Access to data was approved by the VISTA steering committee.

We included patients who had suffered ischaemic stroke whilst taking antiplatelet drugs (for at least 7 days prior) and who were recommenced on antiplatelet therapy within 90 days after ischaemic stroke where data on baseline characteristics, medical history, baseline National Institutes of Health Stroke Scale (NIHSS), occurrence of adverse and serious adverse events, and medication use with start dates were recorded in VISTA. We extracted data for these patients.

Data on antiplatelet treatments were based on platelet aggregation inhibitors (which includes derivatives of salicylic acid, thienopyridine and dipyridamole). Participants

were grouped according to whether they changed antiplatelet regimen (change group) or continued on the same antiplatelet therapy (continue group).

Our primary outcome was the occurrence of recurrent ischaemic stroke and the secondary outcome was bleeding complications within 90 days post-stroke. The modified Rankin Scale (mRS) at 90 days was used to measure the functional outcomes. We extracted information about recurrent ischaemic stroke and bleeding complications in all patients from AE and SAE reports. We defined a recurrent ischaemic stroke as a clear statement of a new adverse event including terms ischaemic stroke, cerebral infarction or cerebrovascular accident. We did not include events such as worsening of initial stroke symptoms or oedema. For bleeding complication, the event was identifies using these key terms: hematoma, haemorrhage, bleeding, blood or melaena. Bleeding complications were categorized into two i.e. intracerebral haemorrhage (ICH) and extracranial haemorrhage (ECH). Intracerebral haemorrhage was defined as any ICH but excluding haemorrhagic transformation infarction 1 and 2, whereas, ECH was defined as any bleeding episode from another source.

Statistical analysis

We compared baseline variables in the change and continue groups. Categorical variables were summarised using frequencies and proportions and were compared using the Chi-square test or Fisher's exact test, where appropriate. Continuous variables were summarised using mean [standard deviation (SD)] or median [interquartile range (IQR)] and were compared using Student t-test or non-parametric Mann-Whitney test.

We calculated adjusted odds ratios (OR) and corresponding 95% confidence intervals (95% CI) using binary logistic regression for occurrence of outcomes and ordinal shift of the mRS at day 90 using the full scale for functional outcomes. Adjustment were made for age and baseline NIHSS.^{9, 10} We also assessed the effect of changed or continued antiplatelet regimen on outcome measures in subgroups: clinical condition (atrial fibrillation or not, prior stroke or not and treated with intravenous thrombolysis or not). We conducted subgroup analyses in these populations as their stroke risk recurrence ^{11, 12} and neurological recovery ¹³ are different. A p-value <0.05 was used to define statistical significance. All analyses were performed using IBM SPSS Version 21.0.¹⁴

Results

A total of 1129 stroke patients met our inclusion criteria (Figure 1). Forty-eight percent were changed to a new antiplatelet drug post-stroke. Patient characteristics as shown in Table 1.

There was no difference in recurrent ischaemic stroke rate between the change and continue groups (adjusted OR=0.97, 95% CI, 0.54-1.75; p=0.929) (Table 2). The rate of ICH and ECH was similar in both groups (2.4% vs. 2.6% [adjusted OR=1.02; 95% CI 0.48-2.18, p=0.955] and 4.7% vs. 2.9% [adjusted OR=1.82; 95% CI 0.96-3.43, p=0.065]) respectively. Results were similar regardless of baseline factors such as atrial fibrillation, history of prior stroke and thrombolysed patients (Figure 2).

The distribution of mRS at 90 days for change versus continue group is shown in Figure 3. We found that change to a new antiplatelet post-stroke was associated with more

favourable functional outcome across a full scale mRS at 90 days after adjustments for age and baseline NIHSS (adjusted OR, 1.48; 95% CI, 1.19-1.86; p=0.0006), compared with continue group.

[insert Figure 1]

Figure 1. Flow diagram describing the selection of data from the VISTA for the analysis reported.

Characteristics	Change (n=538)	Continue (n=591)	p-value	
Age, years*	70.91 (11.25)	72.08 (10.49)	0.091	
Male	332 (61.7)	329 (55.7)	0.040	
Caucasian	469/527 (89.0)	531/571 (93.0)	0.020	
Current Smoker	172/524 (32.8)	145/471 (30.8)	0.491	
Baseline NIHSS†	13 (9-17)	14 (9-18)	0.036	
Medical history				
Hypertension	444/537 (82.7)	448/590 (75.9)	0.005	
Diabetes	153/538 (28.4)	155/590 (26.3)	0.414	
AF	79/537 (14.7)	135/590 (22.9)	<0.001	
Heart failure	48/513 (9.4)	51/548 (9.3)	0.978	
IHD	229/525 (43.6)	204/471 (43.3)	0.922	
Prior TIA	68/490 (13.9)	67/554 (12.1)	0.391	
Prior stroke	190/527 (36.1)	133/568 (23.4)	<0.001	
Thrombolysed, rt-PA	234 (43.5)	174 (29.4)	<0.001	
AP duration post-stroke				
≤ 30 days	109 (20.3)	156 (26.4)	0.041	
31- 60 days	36 (6.7)	31 (5.2)		
61- 90 days	393 (73.0)	404 (68.4)		

Table 1. Baseline characteristics

All values are reported as no. (%) unless otherwise noted. *Values are reported as mean (SD); †median (IQR). AF=atrial fibrillation, AP=antiplatelet, IHD= ischaemic heart disease, NIHSS=National Institutes of Health Stroke Scale, rt-PA=recombinant tissue plasminogen activator. TIA=transient ischaemic attack, SD=standard deviation, IQR=interquartile range.

Outcomes	Change n=538	Continue n=591	Adjusted OR (95% CI)	p-value
Recurrent ischaemic stroke	22/532 (4.1)	25/588 (4.3)	0.97 (0.54-1.75)	0.929
ICH	13/532 (2.4)	15/581 (2.6)	1.02 (0.48-2.18)	0.955
ECH	25/527 (4.7)	17/584 (2.9)	1.82 (0.96-3.43)	0.065

Table 2. Clinical outcomes at 90 days (adjusted for age and baseline NIHSS).

All values are reported as no. (%) unless otherwise noted. CI=confidence interval, ICH=intracranial haemorrhage, ECH=extracranial haemorrhage, OR=odds ratio.

[insert Figure 2]

Figure 2. Clinical outcomes at 90 days (adjusted for age and baseline NIHSS) by subgroup. All values are reported as no. (%) unless otherwise noted. AF=atrial fibrillation, OR=odds ratio, CI=confidence interval.

[insert Figure 3]

Figure 3. Distribution of mRS outcome at day 90 in patients suffering ischaemic stroke. Diagram showing association of functional outcome at day 90 between change and continue group. Values provided in each box denote the percentage of patients belonging to a specific treatment category (change or continue) and representing the mRS score corresponding to the box.

Discussion

In the present study we found that subjects who experience stroke while on antiplatelet therapy and who switch to a new class of antiplatelet regimen after stroke do not have a lower early recurrence rate than subjects who continue with the same antiplatelet therapy. We also found no difference in bleeding outcomes. Furthermore, the clinical outcomes were not significantly different across pre-defined subgroups. We found that change group was associated with an increase in the odds of a favourable functional outcome.

Many patients suffer ischaemic stroke despite taking antiplatelet therapy. Some studies show that, in ischaemic heart disease, patients who are non-responders to aspirin and clopidogrel are at greater risk of subsequent ischaemic vascular event and death.¹⁵ It is therefore attractive to suggest that changing antiplatelet class will be of benefit, and reduce subsequent recurrence, in patients who are admitted with ischaemic stroke despite antiplatelets. This would be a cheap, immediately available way of reducing risk. Another study found the rate of adverse clinical outcomes was significantly higher in antiplatelet-regimen-modified group than those without modification.¹⁶

There are no trials that show changed antiplatelet therapy after a stroke event reducing the risk of subsequent stroke.⁴ A recent retrospective cohort study by Lee et al.¹⁷ compared clopidogrel initiation versus aspirin re-initiation among patients with ischaemic stroke who took aspirin at least 30 days prior to their index of stroke. They found those who changed to clopidogrel after a stroke was associated with fewer vascular events than aspirin. In contrast, we did not find any significant relation between those who change and continue antiplatelet therapy. The reasons might be because our study follow-up was shorter i.e. 90 days compared to study by Lee et al.¹⁷ and other related trials which are normally more than 2 years.¹⁸

Furthermore, we divided patients into two different groups, whether they change or continue with the same antiplatelet therapy and not according to specific antiplatelet agent.

We found those who changed antiplatelet regimen had better functional outcome at 90 days than those in continue group. Although we tried to adjust for differences in baseline factors, this most likely reflects residual confounding and may reflect regional differences in stroke care. A physician may choose a more aggressive (or change) approach in patients with better prognosis. Such differences may affect functional outcomes but not recurrence risk. In our study the change group had lower stroke severity and fewer patients with atrial fibrillation at baseline, both factors are known to associate with an increased risk of poor outcome following an ischaemic stroke.¹⁹⁻²³

There are several limitations to this study. The analysis was performed using a nonrandomized registry data that derived from various clinical trials. Thus, selection and other biases could have confounded antiplatelet therapy choices. The number of included participants was low due to the selection criteria, the need to be on antiplatelet therapy before and after stroke and the need for the start dates of prior and new medications to be recorded. Although the recurrent ischaemic stroke rate was identical between groups, we lack statistical power to exclude a potentially clinically significant difference between groups. We unable to investigate stroke recurrence based on stroke subtype as the information are not available in most of the patients. We lack specific measures of medication compliance, particularly before the stroke, which could be a cause of failure of treatment. The effects of switching drugs class in such patients may be different and this will need to be addressed by further study. We also lack information on discharge time, which could be related to compliance and to functional outcomes. We did not have information on all variables to calculate CHAD2VASC score and only 19% of our patients had AF.

There are also strengths to our study. The data are derived from prospective trials with standardized assessments and careful data monitoring, providing high quality data. In addition, we were able to adjust for the most important prognostic variables.

In summary, we found no difference in outcomes in patients who continued the same antiplatelets after stroke or who changed. Despite no clear evidence for changing antiplatelet strategies following a cardiovascular event, over 50% of patients had their medication changed. This may reflect uncertainty or the fact guidelines. As recommended by the guideline, the selection of antiplatelet regimen after ischaemic stroke however, should be individualized on the basis of patient risk factor profiles, cost, tolerance and other clinical characteristics.⁴ However, this was a small retrospective analysis and future prospective trials will be needed.

Appendix

VISTA-Acute Steering committee members: A.V. Alexandrov, P.W. Bath, E. Bluhmki, L.Claesson, J. Curram, S.M. Davis, G. Donnan, H. C. Diener, M. Fisher, B. Gregson, J. Grotta,W. Hacke, M.G. Hennerici, M. Hommel, M. Kaste, K.R. Lees (Chair), P. Lyden, J. Marler,K. Muir, R. Sacco, A. Shuaib, P. Teal, N.G. Wahlgren, S. Warach, and C. Weimar.

References

1. Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th

ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012; 141: e6015-6365.

2. Gent M, D Beaumont, J Blanchard, et al. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). *Lancet* 1996; 348: 1329-1339.

3. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. *Lancet* 2009; 373: 1849-1860.

4. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2014; 45: 2160-2236.

5. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. *N Engl J Med* 2013; 369: 11-19.

6. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2011; 42: 227-276.

7. Ozben S, Ozben B, Tanrikulu AM, Ozer F and Ozben T. Aspirin resistance in patients with acute ischemic stroke. *J Neurol* 2011; 258: 1979-1986.

8. Ali M, Bath PMW, Curram J, et al. The Virtual International Stroke Trials Archive. *Stroke* 2007; 38: 1905-1910.

9. Konig IR, Ziegler A, Bluhmki E, et al. Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. *Stroke* 2008; 39: 1821-1826.

10. Lees KR, Davalos A, Davis SM, et al. Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial. *Stroke* 2006; 37: 2970-2978.

16

11. Burn J, Dennis M, Bamford J, Sandercock P, Wade D and Warlow C. Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. *Stroke* 1994; 25: 333-337.

12. Penado S, Cano M, Acha O, Hernandez JL and Riancho JA. Atrial fibrillation as a risk factor for stroke recurrence. *Am J Med* 2003; 114: 206-210.

13. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med* 1995; 333: 1581-1587.

14. IBM Corp. IBM SPSS Statistics for Windows. Version 21.0 ed. Armonk, NY: IBM Corp, 2012.

15. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. *J Am Coll Cardiol* 2010; 56: 919-933.

16. Depta JP, Fowler J, Novak E, et al. Clinical outcomes using a platelet functionguided approach for secondary prevention in patients with ischemic stroke or transient ischemic attack. *Stroke* 2012; 43: 2376-2381.

17. Lee M, Wu Y-L, Saver JL, et al. Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study. *BMJ Open* 2014; 4.

18. Sacco RL, Diener H, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. *N Engl J Med* 2008; 359: 1238-1251.

19. McGrath ER, Kapral MK, Fang J, et al. Association of atrial fibrillation with mortality and disability after ischemic stroke. *Neurology* 2013; 81: 825-832.


20. Andersen KK, Andersen ZJ and Olsen TS. Predictors of early and late case-fatality in a nationwide Danish study of 26,818 patients with first-ever ischemic stroke. *Stroke* 2011; 42: 2806-2812.

21. Saposnik G, Kapral MK, Liu Y, et al. IScore: a risk score to predict death early after hospitalization for an acute ischemic stroke. *Circulation* 2011; 123: 739-749.

17

22. Muir KW, Weir CJ, Murray GD, Povey C and Lees KR. Comparison of neurological scales and scoring systems for acute stroke prognosis. *Stroke* 1996; 27: 1817-1820.

23. Adams HP, Jr., Davis PH, Leira EC, et al. Baseline NIH Stroke Scale score strongly predicts outcome after stroke: A report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). *Neurology* 1999; 53: 126-131.



	Change Continue #538 #4581	Adjusted OR (1975-CI)	Adjusted OR (R7% CI)	p-value
Recurrent ischee	mic stroke			
AF.	378 5132 (3.8) (3.8)	_	1.05 (0.24-4.70)	0.946
No AE	19453 29455 (4.2) (4.4)		0.96 (0.51-1.83)	0.906
Prior stroke	4187 7/131 (2.1) (5.3)		0.39 (0.11-1.36)	0.140
No prior stroke	18/334 18/434 (5.4) (4.1)		1.32 (0.68-2.60)	0.414
Thrombolysed	8231 8171 (3.5) (4.7)		0.75 (0.27-2.05)	0.568
Non-twombolysed	14/201 13/417 (4.7) (4.1)		1.14 (0.35-2.36)	0.723
Intracranial haem	ontage			
A5	378 3134 (3.8) (2.2)		2.26 (0.42-12.32)	0.546
No AF	10453 12446 (2.2) (2.7)		0.84 (0.36-1.98)	0.698
Prior stroke	5186 4132 (27) (20)		1.01 (0.26-3.92)	0.985
No prior stroke	8035 9428 (2.4) (2.1)		1.30 (0.49-3.48)	0.596
Thrombolysed	9229 5166 (3.9) (3.0)		1.44 (0.47-4.43)	0.522
Non-thrombolysed	4303 10415 (1.3) (2.4)		0.59 (0.18-1.91)	0.377
Extracrenial haen	northage			
AF.	576 6134		1.65 (0.47-5.84)	0.433
No AF	20450 11449 (4.4) (2.4)		1.93 (0.91-4.09)	0.087
Prior stroke	10/184 6/137 (5.4) (4.6)		1.31 (0.46-3.75)	0.614
No prior stroke	15333 11431		1.98 (0.89-4.41)	0.096
Thrombolysed	8227 3171		2.50 (0.63-9.83)	0.191
Non-thombolysed	17300 14413		1.82 (0.87-3.78)	0.111

Charge befter